Senti Biosciences (NASDAQ: SNTI) stock soared during intraday trading Monday following news that the company secured an $8 million grant from the California Institute for Regenerative Medicines.
Senti Biosciences, a leading biotech company, received an $8 million grant from the California Institute for Regenerative Medicines (CIRM) to support the ongoing clinical development of SENTI-202, a pioneering Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy designed for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).
Timothy Lu, M.D., Ph.D., Chief Executive Officer and Co-Founder of Senti Bio, expressed gratitude to CIRM for their support, highlighting SENTI-202’s potential to improve the lives of patients with AML. He emphasized the company’s commitment to advancing potentially life-saving treatments for cancer patients.
The Phase 1 trial of SENTI-202 is underway, enrolling adult patients with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including AML, across multiple sites in the United States and Australia. The trial aims to evaluate the safety and efficacy of two dose levels—1 billion or 1.5 billion SENTI-202 cells—administered in cycles following disease-specific lymphodepleting conditioning. Patients may receive multiple cycles of treatment based on ongoing safety and efficacy assessments.
The company plans to release initial efficacy data for the Phase 1 clinical trial for SENTI-202 by late 2024, with durability data expected in 2025.
Senti Biosciences (NASDAQ: SNTI) Stock Reaction
SNTI stock surged 51.26% on Monday, closing at $0.4175, marking a 65.67% increase for the week. The trading volume was 389,563,488 shares, significantly higher than the average daily volume of 7.05 million.
NASDAQ: SNTI Senti Biosciences SNTI SNTI shares SNTI stock SNTI stock news
